Dynamics at the serine loop underlie differential affinity of cryptochromes for CLOCK:BMAL1 to control circadian timing

  1. Jennifer L Fribourgh
  2. Ashutosh Srivastava
  3. Colby R Sandate
  4. Alicia K Michael
  5. Peter L Hsu
  6. Christin Rakers
  7. Leslee T Nguyen
  8. Megan R Torgrimson
  9. Gian Carlo G Parico
  10. Sarvind Tripathi
  11. NIng Zheng
  12. Gabriel C Lander
  13. Tsuyoshi Hirota
  14. Florence Tama  Is a corresponding author
  15. Carrie L Partch  Is a corresponding author
  1. UCSC, United States
  2. Nagoya University, Japan
  3. Scripps Research Institute, United States
  4. University of Washington, United States
  5. Kyoto University, Japan

Abstract

Mammalian circadian rhythms are generated by a transcription-based feedback loop in which CLOCK:BMAL1 drives transcription of its repressors (PER1/2, CRY1/2), which ultimately interact with CLOCK:BMAL1 to close the feedback loop with ~24-hour periodicity. Here we pinpoint a key difference between CRY1 and CRY2 that underlies their differential strengths as transcriptional repressors. Both cryptochromes bind the BMAL1 transactivation domain similarly to sequester it from coactivators and repress CLOCK:BMAL1 activity. However, we find that CRY1 is recruited with much higher affinity to the PAS domain core of CLOCK:BMAL1, allowing it to serve as a stronger repressor that lengthens circadian period. We discovered a dynamic serine-rich loop adjacent to the secondary pocket in the photolyase homology region (PHR) domain that regulates differential binding of cryptochromes to the PAS domain core of CLOCK:BMAL1. Notably, binding of the co-repressor PER2 remodels the serine loop of CRY2, making it more CRY1-like and enhancing its affinity for CLOCK:BMAL1.

Data availability

Diffraction data have been deposited in PDB under the accession code 6OF7.

The following data sets were generated

Article and author information

Author details

  1. Jennifer L Fribourgh

    Chemistry and Biochemistry, UCSC, Santa Cruz, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. Ashutosh Srivastava

    Institute of Transformative Bio-Molecules, Nagoya University, Nagoya, Japan
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9820-720X
  3. Colby R Sandate

    Integrative Structural and Computational Biology, Scripps Research Institute, La Jolla, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8758-5931
  4. Alicia K Michael

    Chemistry and Biochemistry, UCSC, Santa Cruz, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Peter L Hsu

    Pharmacology, University of Washington, Seattle, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Christin Rakers

    Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5668-6844
  7. Leslee T Nguyen

    Chemistry and Biochemistry, UCSC, Santa Cruz, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Megan R Torgrimson

    Chemistry and Biochemistry, UCSC, Santa Cruz, United States
    Competing interests
    The authors declare that no competing interests exist.
  9. Gian Carlo G Parico

    Chemistry and Biochemistry, UCSC, Santa Cruz, United States
    Competing interests
    The authors declare that no competing interests exist.
  10. Sarvind Tripathi

    Chemistry and Biochemistry, UCSC, Santa Cruz, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6959-0577
  11. NIng Zheng

    Pharmacology, University of Washington, Seattle, United States
    Competing interests
    The authors declare that no competing interests exist.
  12. Gabriel C Lander

    Structural Biology, Scripps Research Institute, La Jolla, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-4921-1135
  13. Tsuyoshi Hirota

    Institute of Transformative Bio-Molecules, Nagoya University, Nagoya, Japan
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-4876-3608
  14. Florence Tama

    Institute of Transformative bio-Molecules, Nagoya University, Nagoya, Japan
    For correspondence
    florence.tama@nagoya-u.jp
    Competing interests
    The authors declare that no competing interests exist.
  15. Carrie L Partch

    Chemistry and Biochemistry, UCSC, Santa Cruz, United States
    For correspondence
    cpartch@ucsc.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4677-2861

Funding

National Institutes of Health (R01 GM107069)

  • Carrie L Partch

National Institutes of Health (F31 CA189660)

  • Alicia K Michael

National Institutes of Health (S10 OD021634)

  • Gabriel C Lander

UC Cancer Research Coordinating Committee (CRN-15-380548)

  • Carrie L Partch

National Institutes of Health (DP2 EB020402)

  • Gabriel C Lander

RIKEN (Dynamic Structural Biology Project)

  • Florence Tama

Pew Charitable Trusts (Pew Scholar)

  • Gabriel C Lander

Amgen (Young Investigator)

  • Gabriel C Lander

UC Office of the President (Chancellor's Postdoctoral Fellow)

  • Jennifer L Fribourgh

National Science Foundation (Graduate Research Fellowship)

  • Colby R Sandate

Howard Hughes Medical Institute (Gilliam fellowship)

  • Christin Rakers

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2020, Fribourgh et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,646
    views
  • 461
    downloads
  • 54
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Jennifer L Fribourgh
  2. Ashutosh Srivastava
  3. Colby R Sandate
  4. Alicia K Michael
  5. Peter L Hsu
  6. Christin Rakers
  7. Leslee T Nguyen
  8. Megan R Torgrimson
  9. Gian Carlo G Parico
  10. Sarvind Tripathi
  11. NIng Zheng
  12. Gabriel C Lander
  13. Tsuyoshi Hirota
  14. Florence Tama
  15. Carrie L Partch
(2020)
Dynamics at the serine loop underlie differential affinity of cryptochromes for CLOCK:BMAL1 to control circadian timing
eLife 9:e55275.
https://doi.org/10.7554/eLife.55275

Share this article

https://doi.org/10.7554/eLife.55275

Further reading

    1. Biochemistry and Chemical Biology
    2. Structural Biology and Molecular Biophysics
    Jie Luo, Jeff Ranish
    Tools and Resources

    Dynamic conformational and structural changes in proteins and protein complexes play a central and ubiquitous role in the regulation of protein function, yet it is very challenging to study these changes, especially for large protein complexes, under physiological conditions. Here, we introduce a novel isobaric crosslinker, Qlinker, for studying conformational and structural changes in proteins and protein complexes using quantitative crosslinking mass spectrometry. Qlinkers are small and simple, amine-reactive molecules with an optimal extended distance of ~10 Å, which use MS2 reporter ions for relative quantification of Qlinker-modified peptides derived from different samples. We synthesized the 2-plex Q2linker and showed that the Q2linker can provide quantitative crosslinking data that pinpoints key conformational and structural changes in biosensors, binary and ternary complexes composed of the general transcription factors TBP, TFIIA, and TFIIB, and RNA polymerase II complexes.

    1. Biochemistry and Chemical Biology
    2. Stem Cells and Regenerative Medicine
    Alejandro J Brenes, Eva Griesser ... Angus I Lamond
    Research Article

    Human induced pluripotent stem cells (hiPSCs) have great potential to be used as alternatives to embryonic stem cells (hESCs) in regenerative medicine and disease modelling. In this study, we characterise the proteomes of multiple hiPSC and hESC lines derived from independent donors and find that while they express a near-identical set of proteins, they show consistent quantitative differences in the abundance of a subset of proteins. hiPSCs have increased total protein content, while maintaining a comparable cell cycle profile to hESCs, with increased abundance of cytoplasmic and mitochondrial proteins required to sustain high growth rates, including nutrient transporters and metabolic proteins. Prominent changes detected in proteins involved in mitochondrial metabolism correlated with enhanced mitochondrial potential, shown using high-resolution respirometry. hiPSCs also produced higher levels of secreted proteins, including growth factors and proteins involved in the inhibition of the immune system. The data indicate that reprogramming of fibroblasts to hiPSCs produces important differences in cytoplasmic and mitochondrial proteins compared to hESCs, with consequences affecting growth and metabolism. This study improves our understanding of the molecular differences between hiPSCs and hESCs, with implications for potential risks and benefits for their use in future disease modelling and therapeutic applications.